Skip to main content

Table 1 Baseline characteristics compared between HFpEF and controls

From: Impact of different degrees of left ventricular strain on left atrial mechanics in heart failure with preserved ejection fraction

Characteristics HFpEF (n = 79) Controls (n = 158) p-value
Age (years) 71.6 ± 11.5 70.6 ± 10.0 0.491
Male gender 29 (36.7%) 58 (36.7%) 1.000
Body mass index (kg/m2) 26.8 ± 5.6 26.6 ± 4.6 0.767
NYHA-II 68 (86.1%)
NYHA-III 11 (13.9%)
Hyperlipidemia 51 (64.6%) 116 (73.4%) 0.159
Diabetes 44 (55.7%) 85 (53.8%) 0.782
Hypertension 61 (77.2%) 114 (72.2%) 0.403
History of myocardial infarction 5 (6.3%) 0 (0.0%) 0.164
History of revascularization 7 (8.9%) 0 (0%) 0.333
History of atrial fibrillation 19 (24.1%) 2 (1.3%)  < 0.001
Mitral regurgitation 28 (35.4%) 21 (13.3%)  < 0.001
Medication use    
 Aspirin 28 (43.1%) 63 (47.4%) 0.569
 Statin 43 (66.2%) 95 (71.4%) 0.448
 β-blockers 38 (58.5%) 77 (57.9%) 0.939
 ACEi 9 (13.8%) 16 (12.0%) 0.718
 ARB 18 (27.7%) 42 (31.6%) 0.576
 Diuretics 27 (41.5%) 31 (23.3%) 0.008
  1. Data presented as mean ± standard deviation or number and percentage
  2. ACEi angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blockers; HFpEF heart failure with preserved ejection fraction; NYHA New York Heart Association functional class
  3. A p-value < 0.05 indicates statistical significance (bold and italic)
  4. Medication data were available for 83.5% (n = 198) of total subjects